JP2021519089A5 - - Google Patents
Info
- Publication number
- JP2021519089A5 JP2021519089A5 JP2020551924A JP2020551924A JP2021519089A5 JP 2021519089 A5 JP2021519089 A5 JP 2021519089A5 JP 2020551924 A JP2020551924 A JP 2020551924A JP 2020551924 A JP2020551924 A JP 2020551924A JP 2021519089 A5 JP2021519089 A5 JP 2021519089A5
- Authority
- JP
- Japan
- Prior art keywords
- chimeric protein
- protein complex
- complex according
- based chimeric
- domain
- Prior art date
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024006808A JP2024028543A (ja) | 2018-03-28 | 2024-01-19 | 二官能性タンパク質およびその作製 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862649264P | 2018-03-28 | 2018-03-28 | |
| US201862649238P | 2018-03-28 | 2018-03-28 | |
| US201862649248P | 2018-03-28 | 2018-03-28 | |
| US62/649,248 | 2018-03-28 | ||
| US62/649,238 | 2018-03-28 | ||
| US62/649,264 | 2018-03-28 | ||
| PCT/US2019/024714 WO2019191519A1 (en) | 2018-03-28 | 2019-03-28 | Bi-functional proteins and construction thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024006808A Division JP2024028543A (ja) | 2018-03-28 | 2024-01-19 | 二官能性タンパク質およびその作製 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021519089A JP2021519089A (ja) | 2021-08-10 |
| JPWO2019191519A5 JPWO2019191519A5 (https=) | 2022-04-05 |
| JP2021519089A5 true JP2021519089A5 (https=) | 2022-04-05 |
Family
ID=68060793
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020551924A Pending JP2021519089A (ja) | 2018-03-28 | 2019-03-28 | 二官能性タンパク質およびその作製 |
| JP2024006808A Pending JP2024028543A (ja) | 2018-03-28 | 2024-01-19 | 二官能性タンパク質およびその作製 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024006808A Pending JP2024028543A (ja) | 2018-03-28 | 2024-01-19 | 二官能性タンパク質およびその作製 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20210024631A1 (https=) |
| EP (1) | EP3773674A4 (https=) |
| JP (2) | JP2021519089A (https=) |
| KR (1) | KR20210005872A (https=) |
| CN (1) | CN112512551A (https=) |
| AU (2) | AU2019243580A1 (https=) |
| CA (1) | CA3095310A1 (https=) |
| WO (1) | WO2019191519A1 (https=) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109563141A (zh) * | 2016-05-13 | 2019-04-02 | 奥里尼斯生物科学公司 | 对非细胞结构的治疗性靶向 |
| EP3577133A1 (en) * | 2017-02-06 | 2019-12-11 | Orionis Biosciences NV | Targeted chimeric proteins and uses thereof |
| DK3661954T3 (da) | 2017-08-03 | 2022-04-19 | Amgen Inc | Interleukin-21-muteiner og fremgangsmåder til behandling |
| US12091463B2 (en) * | 2017-08-09 | 2024-09-17 | Orionis Biosciences, Inc. | Clec9A binding agents comprising a recombinant heavy-chain only antibody (VHH) |
| EP3737692A4 (en) | 2018-01-09 | 2021-09-29 | Elstar Therapeutics, Inc. | CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES |
| TW201930344A (zh) | 2018-01-12 | 2019-08-01 | 美商安進公司 | 抗ｐｄ-１抗體及治療方法 |
| JP2021513361A (ja) * | 2018-02-05 | 2021-05-27 | オリオニス バイオサイエンシーズ，インコーポレイテッド | 線維芽細胞結合物質およびその使用 |
| US12152073B2 (en) | 2018-03-14 | 2024-11-26 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| CN108727504B (zh) * | 2018-04-16 | 2021-08-27 | 泉州向日葵生物科技有限公司 | 一种ifn与抗pd-l1抗体的融合蛋白及其应用 |
| EP3818083A2 (en) | 2018-07-03 | 2021-05-12 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| CN120463822A (zh) | 2018-09-27 | 2025-08-12 | 西里欧发展公司 | 掩蔽型细胞因子多肽 |
| US12410225B2 (en) * | 2018-11-08 | 2025-09-09 | Orionis Biosciences, Inc | Modulation of dendritic cell lineages |
| JP7710373B2 (ja) | 2019-02-21 | 2025-07-18 | マレンゴ・セラピューティクス，インコーポレーテッド | Ｔ細胞関連のがん細胞に結合する多機能性分子およびその使用 |
| AU2020224681A1 (en) | 2019-02-21 | 2021-09-16 | Marengo Therapeutics, Inc. | Antibody molecules that bind to NKp30 and uses thereof |
| US12006345B2 (en) | 2019-02-21 | 2024-06-11 | Xencor, Inc. | Untargeted and targeted IL-10 Fc-fusion proteins |
| JP7729778B2 (ja) * | 2019-03-28 | 2025-08-26 | オリオニス バイオサイエンシズ，インコーポレイテッド | Ｆｍｓ様チロシンキナーゼ３（ｆｌｔ３）に対するキメラタンパク質およびキメラタンパク質複合体 |
| CN120590542A (zh) | 2019-03-28 | 2025-09-05 | 奥里尼斯生物科学股份有限公司 | 基于clec9a的嵌合蛋白复合物 |
| CA3133648A1 (en) | 2019-03-28 | 2020-10-01 | Orionis Biosciences, Inc. | Fibroblast activation protein binding agents and use thereof |
| JP7689079B2 (ja) | 2019-03-28 | 2025-06-05 | オリオニス バイオサイエンシズ，インコーポレイテッド | 治療用インターフェロンアルファ１タンパク質 |
| JP7641912B2 (ja) | 2019-04-19 | 2025-03-07 | シナーキン・ファーマ・ベスローテン・フエンノートシャップ | Ｉｌ１３を含む融合タンパク質 |
| JPWO2020250706A1 (https=) | 2019-06-12 | 2020-12-17 | ||
| US11636771B2 (en) | 2019-09-08 | 2023-04-25 | Deere & Company | Stackable housing containers and related systems |
| KR20220109436A (ko) | 2019-12-03 | 2022-08-04 | 에보텍 인터내셔널 게엠베하 | 인터페론-결합된 항원 결합 단백질 및 이의 용도 |
| AR120698A1 (es) | 2019-12-09 | 2022-03-09 | Ablynx Nv | Polipéptidos que comprenden dominios variables únicos de inmunoglobulina que se dirigen a il-13 y tslp |
| WO2021116182A1 (en) * | 2019-12-09 | 2021-06-17 | Ablynx Nv | Polypeptides comprising immunoglobulin single variable domains targeting il-13 and tslp |
| CN116234829A (zh) | 2020-01-03 | 2023-06-06 | 马伦戈治疗公司 | 抗tcr抗体分子及其用途 |
| WO2021144415A1 (en) * | 2020-01-17 | 2021-07-22 | Universiteit Gent | Immunoglobulin single domain antibodies for delivery of mucosal vaccines |
| EP4130041A4 (en) * | 2020-03-31 | 2024-05-22 | Biotheus Inc. | ANTI-PD-L1 AND PD-L2 ANTIBODIES AND DERIVATIVES AND USE THEREOF |
| KR20210141311A (ko) * | 2020-05-14 | 2021-11-23 | 주식회사 제넥신 | Pd-l1 단백질 및 단량체성 il-10 변이체가 포함된 융합 단백질 및 이의 용도 |
| EP4178609A4 (en) * | 2020-07-07 | 2024-07-24 | Orionis Biosciences, Inc. | IMMUNOSTIMULATORY ADJUVANTS |
| JP2023541601A (ja) | 2020-09-10 | 2023-10-03 | プレシリックス・ナームローゼ・ベンノートシヤープ | Ｆａｐに対する抗体フラグメント |
| EP4232071A4 (en) | 2020-10-23 | 2024-08-28 | Asher Biotherapeutics, Inc. | FUSIONS WITH CD8 ANTIGEN-BINDING MOLECULES TO MODULATE IMMUNE CELL FUNCTION |
| WO2022089418A1 (zh) * | 2020-10-26 | 2022-05-05 | 信达生物制药(苏州)有限公司 | 重组截短FLT3配体与人抗体Fc的融合蛋白 |
| US20250186520A1 (en) * | 2020-10-26 | 2025-06-12 | City Of Hope | Oncolytic virus compositions and methods for the treatment of cancer |
| WO2022115865A2 (en) | 2020-11-25 | 2022-06-02 | Xilio Development, Inc. | Tumor-specific cleavable linkers |
| CA3205467A1 (en) * | 2020-12-18 | 2022-06-23 | Bioardis, Llc | Fap binding molecules and uses thereof |
| US20240199714A1 (en) * | 2021-04-16 | 2024-06-20 | Orionis Biosciences, Inc. | Il-2 based constructs |
| AU2022275666A1 (en) | 2021-05-19 | 2023-12-07 | Asher Biotherapeutics, Inc. | Il-21 polypeptides and targeted constructs |
| TW202309102A (zh) * | 2021-07-20 | 2023-03-01 | 美商英伊布里克斯公司 | 靶向cd8之經修飾il-2多肽及其用途 |
| CA3228064A1 (en) * | 2021-08-12 | 2023-02-16 | Shanghai Jmt-Bio Technology Co., Ltd. | Gpc3-targeted antibody interferon .alpha. fusion protein and use thereof |
| EP4395895A1 (en) * | 2021-08-30 | 2024-07-10 | Inhibrx, Inc. | Nkp46-binding polypeptides and uses thereof |
| US20240376198A1 (en) * | 2021-08-30 | 2024-11-14 | Inhibrx, Inc. | NKp46-Targeted Modified IL-2 Polypeptides and Uses Thereof |
| WO2023037015A1 (en) * | 2021-09-13 | 2023-03-16 | Universiteit Gent | Aminopeptidase n-specific monoclonal antibodies and uses thereof |
| EP4408479A4 (en) * | 2021-09-30 | 2026-03-04 | Orionis Biosciences Inc | Split human ifn-gamma and tnf-alpha constructs and uses thereof |
| JP2025512965A (ja) * | 2022-04-07 | 2025-04-22 | アレタ・バイオセラピューティクス・インコーポレイテッド | がんの治療のための組成物及び方法 |
| WO2023201051A2 (en) * | 2022-04-15 | 2023-10-19 | Palleon Pharmaceuticals Inc. | Anti-inflammatory siglec-6 proteins and methods of making and using same |
| WO2023203135A1 (en) | 2022-04-22 | 2023-10-26 | Precirix N.V. | Improved radiolabelled antibody |
| CA3251753A1 (en) | 2022-05-02 | 2023-11-09 | Precirix N.V. | PRE-TARGETTING |
| CN116144668A (zh) * | 2023-02-13 | 2023-05-23 | 杭州吉倍思生物制药有限公司 | 人il-1r1基因、蛋白、同源二聚体蛋白质与用途 |
| TW202525857A (zh) * | 2023-09-11 | 2025-07-01 | 大陸商上海才致藥成生物科技有限公司 | 長效副甲狀腺激素受體促效劑融合蛋白及其應用 |
| WO2025106775A1 (en) * | 2023-11-17 | 2025-05-22 | Orionis Biosciences, Inc. | Pd-l1-based chimeric protein formulations |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60327199D1 (de) * | 2002-04-26 | 2009-05-28 | Chugai Pharmaceutical Co Ltd | Verfahren zum screening auf agonistische antikörper |
| EP2343081A1 (en) * | 2009-12-31 | 2011-07-13 | Rijksuniversiteit Groningen | Interferon analogs |
| CN103796670A (zh) * | 2011-07-08 | 2014-05-14 | 比奥根艾迪克依蒙菲利亚公司 | 因子viii嵌合和杂合多肽及其使用方法 |
| US9738707B2 (en) * | 2011-07-15 | 2017-08-22 | Biogen Ma Inc. | Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto |
| ES2800426T3 (es) * | 2012-03-03 | 2020-12-30 | Immungene Inc | Moléculas de fusión anticuerpos-mutante de interferón modificadas |
| EP3008093A1 (en) * | 2013-06-11 | 2016-04-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-her2 single domain antibodies, polypeptides comprising thereof and their use for treating cancer |
| CA2965414C (en) * | 2014-10-29 | 2024-01-09 | Teva Pharmaceuticals Australia Pty Ltd | Interferon .alpha.2.beta. variants |
| MA41460A (fr) * | 2015-02-03 | 2017-12-12 | Oncomed Pharm Inc | Agents de liaison à la tnfrsf et leurs utilisations |
| US11702477B2 (en) * | 2015-11-06 | 2023-07-18 | Orionis Biosciences BV | Bi-functional chimeric proteins and uses thereof |
| US11001631B2 (en) * | 2016-02-05 | 2021-05-11 | Orionis Biosciences BV | Clec9A binding agents |
| IL260957B2 (en) * | 2016-02-09 | 2023-11-01 | Bracco Suisse Sa | Chimeric, Recombinant Protein Glycoprotein Selectin-P Ligand-1 (PSGL-1) Conjugates, Preparations Containing Them and Uses Thereof |
| WO2017165464A1 (en) * | 2016-03-21 | 2017-09-28 | Elstar Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
-
2019
- 2019-03-28 US US17/042,512 patent/US20210024631A1/en active Pending
- 2019-03-28 EP EP19775640.6A patent/EP3773674A4/en active Pending
- 2019-03-28 AU AU2019243580A patent/AU2019243580A1/en not_active Abandoned
- 2019-03-28 WO PCT/US2019/024714 patent/WO2019191519A1/en not_active Ceased
- 2019-03-28 CA CA3095310A patent/CA3095310A1/en active Pending
- 2019-03-28 KR KR1020207031008A patent/KR20210005872A/ko not_active Ceased
- 2019-03-28 JP JP2020551924A patent/JP2021519089A/ja active Pending
- 2019-03-28 CN CN201980035145.6A patent/CN112512551A/zh active Pending
-
2024
- 2024-01-19 JP JP2024006808A patent/JP2024028543A/ja active Pending
-
2025
- 2025-05-28 AU AU2025203995A patent/AU2025203995A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021519089A5 (https=) | ||
| JPWO2019191519A5 (https=) | ||
| AU2022218544B2 (en) | Hetero-dimeric multi-specific antibody format | |
| Sedykh et al. | Bispecific antibodies: design, therapy, perspectives | |
| Kontermann | Dual targeting strategies with bispecific antibodies | |
| EP3443006B1 (en) | Trispecific and/or trivalent binding proteins | |
| Nuñez-Prado et al. | The coming of age of engineered multivalent antibodies | |
| JP2021118723A5 (https=) | ||
| JP2022511135A (ja) | アルブミン結合ドメイン融合タンパク質 | |
| JP7486810B2 (ja) | ＩｇＧ１ Ｆｃモノマー、及びその使用 | |
| JP2020036595A5 (https=) | ||
| US12428493B2 (en) | Antibodies that bind PSMA and gamma-delta T cell receptors | |
| JP2010517538A5 (https=) | ||
| JPWO2002033073A1 (ja) | 低分子化アゴニスト抗体 | |
| CA2411374A1 (en) | Dual specificity antibodies and methods of making and using | |
| CN116284396B (zh) | NKp46抗体及其用途 | |
| JPWO2021142471A5 (https=) | ||
| IL300062A (en) | Dual fused cytokine proteins containing IL-10 | |
| Rossi et al. | Redirected T-cell killing of solid cancers targeted with an anti-CD3/Trop-2–bispecific antibody is enhanced in combination with interferon-α | |
| US20110165122A1 (en) | Method for targeted and sustained antiviral therapy | |
| WO2001079494A1 (fr) | Anticorps agonistes | |
| JP2002544172A5 (https=) | ||
| RS64771B1 (sr) | Trispecifični i/ili trovalentni vezujući proteini | |
| JPWO2020191342A5 (https=) | ||
| JPWO2021231773A5 (https=) |